A. Salapatek

459 total citations
18 papers, 179 citations indexed

About

A. Salapatek is a scholar working on Immunology and Allergy, Physiology and Dermatology. According to data from OpenAlex, A. Salapatek has authored 18 papers receiving a total of 179 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology and Allergy, 8 papers in Physiology and 5 papers in Dermatology. Recurrent topics in A. Salapatek's work include Allergic Rhinitis and Sensitization (15 papers), Asthma and respiratory diseases (8 papers) and Food Allergy and Anaphylaxis Research (4 papers). A. Salapatek is often cited by papers focused on Allergic Rhinitis and Sensitization (15 papers), Asthma and respiratory diseases (8 papers) and Food Allergy and Anaphylaxis Research (4 papers). A. Salapatek collaborates with scholars based in Canada and United States. A. Salapatek's co-authors include Annemie Narkus, D. Häfner, Mark Larché, Deepen Patel, Paul Laidler, Victoria A. Nelson, William S. Trimble, Peter Couroux, Nicholas E. Diamant and Herbert Y. Gaisano and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, American Journal of Physiology-Cell Physiology and American Journal of Physiology-Gastrointestinal and Liver Physiology.

In The Last Decade

A. Salapatek

16 papers receiving 170 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Salapatek Canada	8	135	123	38	21	18	18	179
Ruby Pawankar Japan	8	206 1.5×	176 1.4×	96 2.5×	12 0.6×	12 0.7×	11	256
Niccolò Gori Italy	9	75 0.6×	48 0.4×	143 3.8×	7 0.3×	25 1.4×	24	188
Xinyan Cui China	6	52 0.4×	72 0.6×	14 0.4×	12 0.6×	12 0.7×	16	132
Schiela Jensen Denmark	3	27 0.2×	44 0.4×	95 2.5×	9 0.4×	4 0.2×	3	126
Carolyn Buckley United Kingdom	5	24 0.2×	20 0.2×	29 0.8×	23 1.1×	9 0.5×	11	92
Sancheng Cao China	4	20 0.1×	46 0.4×	2 0.1×	64 3.0×	38 2.1×	6	166
Berglind Aðalsteinsdóttir Iceland	5	15 0.1×	26 0.2×	3 0.1×	66 3.1×	9 0.5×	6	142
Laura Polivka France	6	15 0.1×	8 0.1×	10 0.3×	10 0.5×	2 0.1×	14	81
Mauro Novali Italy	7	8 0.1×	92 0.7×	1 0.0×	25 1.2×	16 0.9×	16	159
T. Fujioka Japan	4	17 0.1×	8 0.1×	15 0.4×	4 0.2×	2 0.1×	11	95

Countries citing papers authored by A. Salapatek

Since Specialization

Citations

This map shows the geographic impact of A. Salapatek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Salapatek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Salapatek more than expected).

Fields of papers citing papers by A. Salapatek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Salapatek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Salapatek. The network helps show where A. Salapatek may publish in the future.

Co-authorship network of co-authors of A. Salapatek

This figure shows the co-authorship network connecting the top 25 collaborators of A. Salapatek. A scholar is included among the top collaborators of A. Salapatek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Salapatek. A. Salapatek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Salapatek, A., et al.. (2015). Initial Evidence of Sustained Efficacy of House Dust Mite Synthetic Peptide Immuno Regulatory Epitopes 2 Years after a Short Course of Treatment in House Dust Mite (HDM) Allergic Subjects. Journal of Allergy and Clinical Immunology. 135(2). AB142–AB142. 4 indexed citations

Murdoch, Robert, Philippe Bareille, Diane M. Ignar, et al.. (2015). Once-daily dosing of levocabastine has comparable efficacy to twice-daily dosing in the treatment of allergic rhinitis assessed in an allergen challenge chamber. International Journal of Clinical Pharmacology and Therapeutics. 53(10). 811–818. 4 indexed citations

Couroux, Peter, et al.. (2014). Persistent Treatment Effect Achieved At One Year After Four Doses Of Der p Derived Synthetic Peptide Immuno-Regulatory Epitopes In An Exposure Chamber Model Of House Dust Mite Allergy. Journal of Allergy and Clinical Immunology. 133(2). AB289–AB289. 17 indexed citations

Narkus, Annemie, et al.. (2013). Double‐blind, placebo‐controlled, dose‐ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Allergy. 68(6). 724–731. 53 indexed citations

Hafner, Roderick P., Peter Couroux, A. Salapatek, et al.. (2013). Immunotherapy – 2080. Fel d 1 derived peptide antigen desensitization results in a persistent treatment effect on symptoms of cat allergy 1 year after 4 doses. World Allergy Organization Journal. 6. P162–P162. 4 indexed citations

Hafner, Roderick P., Piyush M. Patel, A. Salapatek, et al.. (2013). Immunotherapy – 2067. FEL d 1 peptide antigen desensitization safety and efficacy in a double-blind, placebo-controlled environmental exposure chamber study. World Allergy Organization Journal. 6. P150–P150. 7 indexed citations

Bernstein, Jonathan A., A. Salapatek, Victoria A. Nelson, et al.. (2012). Provocation of nonallergic rhinitis subjects in response to simulated weather conditions using an environmental exposure chamber model. Allergy and Asthma Proceedings. 33(4). 333–340. 22 indexed citations

Salapatek, A., et al.. (2012). A Retrospective Analysis of Anti-Allergy Drug Efficacy tested in an Environmental Exposure Chamber (EEC) Model compared to that observed in the Traditional Allergy Field Trials demonstrates the clinical relevance of allergen exposure models. Journal of Allergy and Clinical Immunology. 129(2). AB207–AB207. 1 indexed citations

Salapatek, A., et al.. (2012). Validation of Peptide Immunotherapy as a New Approach in the Treatment of Allergic Rhinoconjunctivitis: The Clinical Benefits of Treatment with Amb a 1 Derived T cell Epitopes. Journal of Allergy and Clinical Immunology. 129(2). AB368–AB368. 18 indexed citations

10.

Salapatek, A., et al.. (2011). Ectoin®, a Novel, Non-Drug, Extremophile-Based Device, Relieves Allergic Rhinoconjunctivitis Symptoms in Patients in an Environmental Exposure Chamber Model. Journal of Allergy and Clinical Immunology. 127(2). AB202–AB202. 11 indexed citations

11.

Wilson, David, et al.. (2011). Repeated Low-dose Aerosolized Dust Mite Allergen Exposure In Asthmatic And Non-asthmatic Dust Mite Allergic Patients In An Environmental Exposure Chamber Induces Specific Asthma Symptoms As Well As Allergic Rhinoconjunctivitis Symptoms. Journal of Allergy and Clinical Immunology. 127(2). AB20–AB20. 2 indexed citations

12.

Salapatek, A., et al.. (2009). Novel Combination Product Captisol-Enabled® Budesonide + Azelastine HCl Provides Fast, Long-lasting Relief of Allergic Rhinitis Symptoms (Total Nasal Symptom Score (TNSS) and Individual Nasal Symptoms Scores (NSS)) in Ragweed Allergic Patients Studied in an Environmental Exposure Chamber (EEC) Model. Journal of Allergy and Clinical Immunology. 123(2). S130–S130. 1 indexed citations

13.

Salapatek, A., et al.. (2009). Assessment of Total Nasal Symptom Score (TNSS) during the Validation of a Novel Aerosolized Cat Dander Environmental Exposure Chamber (EEC) Clinical Model.. A5704–A5704. 2 indexed citations

14.

Patel, Piyush M., et al.. (2009). The Combination Product Captisol-Enabled® Budesonide + Azelastine HCl Nasal Spray Provides Significant, Long-lasting Relief of Ocular Allergy Symptoms in Ragweed Allergic Patients Studied in an Environmental Exposure Chamber (EEC). Journal of Allergy and Clinical Immunology. 123(2). S130–S130. 1 indexed citations

15.

Salapatek, A., et al.. (2008). Quality of Life (QOL) in Ragweed Allergic Patients Treated with Captisol-Enabled® Budesonide Nasal Solution (32μg/spray) when Exposed to Ragweed Pollen in an Environmental Exposure Chamber (EEC) Using an EEC-Specific Rhinoconjunctivitis Quality of Life Questionnaire (EEC-RQOLQ). Journal of Allergy and Clinical Immunology. 121(2). S55–S55. 1 indexed citations

16.

Patel, Piyush M., et al.. (2007). Tree Pollen Allergoids in Pollinex Quattro Tree Immunotherapy Reduce the Residual Allergenicity as Assessed with Skin Prick Tests (SPTs). Journal of Allergy and Clinical Immunology. 119(1). S57–S57. 1 indexed citations

17.

Huang, Xiaohang, Youhou Kang, Laura Sheu, et al.. (2001). Ca²⁺ influx and cAMP elevation overcame botulinum toxin A but not tetanus toxin inhibition of insulin exocytosis. American Journal of Physiology-Cell Physiology. 281(3). C740–C750. 22 indexed citations

18.

Salapatek, A., et al.. (1992). Mechanism of action of cholecystokinin octapeptide on cat lower esophageal sphincter. American Journal of Physiology-Gastrointestinal and Liver Physiology. 263(3). G419–G425. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact